EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION
Clinical trials for EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION trials appear
Sign up with your email to follow new studies for EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody EPI-326 enters first human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…
Matched conditions: EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Real-World study tracks osimertinib combo for lung cancer
Knowledge-focused Recruiting nowThis study is watching how patients with EGFR-mutated non-small cell lung cancer do when they receive standard treatment with osimertinib (Tagrisso) alone or with chemotherapy in routine medical practice. About 538 people with advanced lung cancer will be followed to see how long…
Matched conditions: EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION
Sponsor: PrECOG, LLC. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC